Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Tianli Biotech Pty Ltd. is currently navigating 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution data reveals a singular focus, with the portfolio being handled by 1 distinct examiner and 1 distinct art unit. This arrangement suggests that the company's current patent efforts are concentrated on a specific innovation that fits within a single administrative division of the patent office.
The busiest examiner for Tianli Biotech Pty Ltd. is YOO, SUN JAE, who is managing 1 busiest examiner pending office action. This individual is responsible for the only active examination for the company, meaning their specific interpretation of the prior art will be the deciding factor for this application. Because there is only 1 distinct art unit, the company avoids the complications of differing examination standards across multiple units.
The prosecution strategy is therefore simplified, focusing on the 1 pending office action and the specific requirements of YOO, SUN JAE. Practitioners should evaluate the examiner's history within the Biotechnology & Pharmaceuticals area to better anticipate potential hurdles. Successfully addressing the 1 pending office action with this 1 examiner is the critical path for the company's patent development.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| No statute on record | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YOO, SUN JAE | 1 | 71.1% | +0.3% |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17291694 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY DISEASES | YOO, SUN JAE | 1621 | — | Non-Final OA | — | Pending | May 06, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial